Journals / Ege Tıp Dergisi / 2019 / Cilt: 58 - Sayı: 0

New therapy methods in osteoarthritis

Osteoartrozda yeni tedavi yöntemleri

Pages
14–21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Some challenges remain, but opportunities for improving symptoms and disease process in OA in the clinic with new pharmacological agents would appear to be on the close horizon.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Osteoarthritis (OA) is the most common form of arthritis.
📊
Key Findings & Data:Despite the many challenges presented by clinical trials in OA, improvements in our understanding of disease pathogenesis and a move to treat pain, as well as underlying disease process, mean there are now many new pharmacological therapies currently in various stages of clinical trials.
💡
Conclusion & Impact:Some challenges remain, but opportunities for improving symptoms and disease process in OA in the clinic with new pharmacological agents would appear to be on the close horizon.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Osteoarthritis (OA) is the most common form of arthritis. Despite the many challenges presented by clinical trials in OA, improvements in our understanding of disease pathogenesis and a move to treat pain, as well as underlying disease process, mean there are now many new pharmacological therapies currently in various stages of clinical trials. Some challenges remain, but opportunities for improving symptoms and disease process in OA in the clinic with new pharmacological agents would appear to be on the close horizon.

Özet

Osteoartroz (OA) en yaygın artrit şeklidir. OA'da klinik çalışmaların sunduğu birçok zorluğa rağmen, hastalık patogenezi, hastalık süreci ve ağrının tedavisinin yanı sıra altta yatan hastalığın tedavisinde birçok yeni farmakolojik tedaviler ve klinik araştırmalar vardır. Yeni farmakolojik ajanlar ile klinikte OA'da semptomların ve hastalık sürecinin iyileştirilmesine yönelik fırsatlar ufukta görünmektedir.

🔖

Cite This Article

ÖZER, D., EYİGÖR, S. (2019). New therapy methods in osteoarthritis. Ege Tıp Dergisi, Cilt: 58 - Sayı: 0, 14–21. https://ajindex.com/articles/158337

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Watt FE, Gulati M. New Drug Treatments for Osteoarthritis: What is on the horizon? EMJ 2017;2: 50-8
  2. Ondresik M, Maia FRA, Morais AS, et al. Management of knee osteoarthritis. Current status and future trends. Biotechnol Bioeng 2017;114:717-39
  3. Cucchiarini M, Henrionnet C, Mainard D, et al. New trends in articular cartilage repair. J Exp Orthop 2015; 2:8. DOI 10.1186/s40634-015-0026-0 4. Mobasheri A. The Future of Osteoarthritis Therapeutics: Targeted Pharmacological Therapy. Curr Rheumatol Rep 2013;15:364. doi: 10.1007/s11926-013-0385-4
  4. Smith SR, Deshpande BR, Collins JE, Katz JN, Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage 2016;24(6):962-72
  5. Bingham CO, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54(11):3494-507
  6. Rossini M, Adami S, Fracassi E, et al. Effects of intra- articular clodronate in the treatment of knee osteoarthritis: results of a double- blind, randomized placebo-controlled trial. Rheumatol Int 2015;35(2):255-63
  7. Laslett LL, Kingsbury SR, Hensor EM, Bowes MA, Conaghan PG. Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. Ann Rheum Dis 2014;73(5):824-30
  8. Walzer SM, Weinmann D, Toegel S. Medical Plant Extracts for Treating Knee Osteoarthritis: a Snapshot of Recent Clinical Trials and Their Biological Background. Curr Rheumatol Rep 2015;17(18):54. doi: 10.1007/s11926-015-0530-3
  9. Pelletier JP, Roubille C, Raynauld JP, et al. Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Ann Rheum Dis 2015;74(2):422-9
  10. Roubille C, Pelletier JM, Raynauldet JP, et al. Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial. Arthritis Res Ther 2015;17:82. doi: 10.1186/s13075-015-0579-4 12. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for cli